Hit enter to search or ESC to close

Author: Alterity Therapeutics

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

– ATH434 shows promise as a disease-modifying therapy for MSA – – ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 October 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease ...

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer  

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 September 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today. “We look forward to Abby’s contributions whose ...

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

– Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data – Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 23 September 2024:      Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2024 (Q4 ...

Alterity Therapeutics to Present at MST Financial Webinar

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 24 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. Details are ...

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 July ...

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 13 June 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ ...

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

– New bioMUSE Data Informs ATH434-202 Study Endpoints – – Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 May 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, ...